This is particularly relevant for GR signaling in ENZ-resistant PCa, as glucocorticoids are commonly administered to PCa patients to alleviate therapy-related side effects and reduce inflammation [8]. The gene discussed is NR3C1; the disease is posterior cortical atrophy.